DAVENPORT & Co LLC Has $146.64 Million Stake in Novo Nordisk A/S $NVO

DAVENPORT & Co LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 54.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,642,498 shares of the company’s stock after buying an additional 935,468 shares during the quarter. Novo Nordisk A/S comprises approximately 0.8% of DAVENPORT & Co LLC’s investment portfolio, making the stock its 29th biggest position. DAVENPORT & Co LLC owned about 0.06% of Novo Nordisk A/S worth $146,644,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the second quarter valued at about $37,000. State of Wyoming bought a new stake in Novo Nordisk A/S during the first quarter worth about $38,000. Maseco LLP bought a new stake in Novo Nordisk A/S during the second quarter worth about $39,000. Finally, Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after buying an additional 186 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of oral Wegovy — market catalyst: The FDA cleared the first oral GLP‑1 pill for weight management, giving Novo a first‑mover commercial advantage and a path to regain share lost to Eli Lilly. Read More.
• Positive Sentiment: Launch plan and pricing expected to drive near‑term sales: Novo plans a U.S. launch in early January with an introductory cash price (~$149/month for starting dose), targeting the large self‑pay market. This gives investors a near-term revenue catalyst. Read More.
• Positive Sentiment: Unusual options activity and strong volume — investor conviction: Large call buying and much higher-than-normal trading volume indicate speculative and directional interest tied to the approval. Read More.
• Positive Sentiment: Analyst commentary supportive: Some analysts (e.g., HSBC cited in recent coverage) see Novo as having an edge over Eli Lilly after getting to market first with an oral option. Read More.
• Neutral Sentiment: ETF and sector flows may amplify moves: Approval has renewed interest in health‑care/GLP‑1 ETFs, which could lift peers and the sector irrespective of Novo’s fundamentals. Read More.
• Neutral Sentiment: Demand and reimbursement are untested for a cash‑market pill: Novo will initially push the pill into self‑pay channels, so uptake and conversion to covered prescriptions remain uncertain and could temper sales growth. Read More.
• Negative Sentiment: Competitive risk from Eli Lilly and others: Analysts warn Lilly’s oral development and its strong injectable momentum remain a material competitive threat; timing of Lilly’s response could cap upside. Read More.
• Negative Sentiment: Regulatory/generic noise in other markets: Separate regulatory delays for generics and local reimbursement issues (e.g., Canada) highlight ongoing access and pricing risks outside the U.S. Read More.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVO. Morgan Stanley reaffirmed an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday. Jefferies Financial Group started coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating on the stock. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $51.66 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The stock has a market cap of $230.65 billion, a PE ratio of 15.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The firm’s fifty day moving average price is $49.55 and its two-hundred day moving average price is $57.16.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.